Sale

Recombinant Vaccines Market

Global Recombinant Vaccines Market: Share, Size, Trends, Growth, Report, Forecast: By Type: Live Attenuated, Subunit; By Disease Indication: Hepatitis B, Rotavirus, Herpes Zoster, Meningococcal B, Others; By Distribution Channel: Hospitals, Vaccination Centres; By End User: Paediatrics, Others; Regional Analysis; Supplier Landscape; 2024-2032

Global Recombinant Vaccines Market Outlook

The value of the global recombinant vaccine market was USD 14.91 billion in 2023, driven by the technological advancements in vaccine development across the globe. The market value is expected to grow at a CAGR of 11.9% during the forecast period of 2024-2032 to reach a value of USD 41.04 billion by 2032.

 

Key Trends in the Market

Recombinant vaccines are vaccines made with DNA recombination, primarily based on yeast or bacterial cells that are embedded into the host cell to trigger an immune response. Some examples of recombinant vaccines are vaccines against meningitis, hepatitis B, and Influenza B diseases. Recombinant vaccines are less risky, can be produced easily and are also capable of being inserted into multiple carriers. 

 

  • Rapid increase in the number of people affected by the zoonotic diseases such as plague, rabies, zoonotic influenza, among other diseases, is expected to increase the demand for recombinant vaccines, fuelling the market growth.
  • Key players have been constantly carrying out research and developments for recombinant vaccines with improved protective abilities which is expected to help in the growth of the market.
  • Reduced hospital expenditure and reduced side effects of using the recombinant vaccines in comparison to other vaccines has increased its use and demand contributing to the growth of the recombinant vaccines market.

 

recombinant vaccines market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Analysis

Based on type, the market can be bifurcated into live attenuated and subunit. By disease indication, the market is divided into hepatitis B, rotavirus, herpes zoster, and meningococcal B, among others. On the basis of end use, the market is segmented into paediatrics, adults, and veterinary. By region, the market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.

 

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global recombinant vaccines market covering their competitive landscape and latest developments like mergers, acquisitions, investments, and expansion plans.

 

  • GSK plc
  • Pfizer Inc.
  • Sanofi
  • Walvax Biotechnology Co., Ltd. (Walvax)
  • Dynavax Technologies Corporation
  • Others

 

recombinant vaccines market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Share by Type

Subunit types of recombinant vaccines are expected to hold a substantial share in the recombinant vaccines market because it does not contain whole virus or bacteria. Containing specific antigens helps these vaccines focus on a small number of antigens. It might require the person to take repeated doses but is considered safer to use in comparison to live attenuated vaccine. 

 

Live attenuated recombinant vaccines contain weakened forms of the virus they protect against. Although they provide long-lasting effects, they may not be suitable for people with weak immune systems. In people with weak immune systems, live attenuated recombinant vaccines risk causing the disease. 

 

Market Share by End Use

Adult end users are a leading shareholder in the recombinant vaccines market because of increasing number of adult patients that are proactively protecting themselves from infectious diseases. This has increased the demand for recombinant vaccine to protect against diseases other vaccine do not prevent, thereby increasing its production. Due to the strong nature of recombinant vaccines, it is safer to give them to adults that can monitor and report any side effects, and have relatively stronger immune systems as compared to children. With new recombinant vaccines released, adults have a wider option to choose from. 

 

recombinant vaccines market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Competitive Landscape

GSK plc is pharmaceutical and biotechnology company that has its headquarter in Brentford, United Kingdom. It was founded in 2000 and manufactures specialty medicines along with innovative vaccines for the prevention and treatment of diseases. 

 

Pfizer Inc. founded in 1849 is headquartered in New York, United States. It is a specialised biotechnology and pharmaceutical company that develop and sell vaccines, medical devices, medicines, and healthcare products for treating diseases.

 

Sanofi was established in 2004 and is based out of Paris, France. A pharmaceutical and healthcare company, it aims to fulfil the health needs of people. They manufacture and sell various health products including vaccines and medicines. 

 

Other market players include Walvax Biotechnology Co., Ltd. (Walvax), and Dynavax Technologies Corporation, among others.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Disease Indication
  • Distribution Channel
  • End User
  • Region
Breakup by Type
  • Live Attenuated
  • Subunit
Breakup by Disease Indication
  • Hepatitis B
  • Rotavirus
  • Herpes Zoster
  • Meningococcal B
  • Others
Breakup by Distribution Channel
  • Hospitals
  • Vaccination Centres
Breakup by End User
  • Paediatrics
  • Adults
  • Veterinary
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • GSK plc
  • Pfizer Inc.
  • Sanofi
  • Walvax Biotechnology Co., Ltd. (Walvax)
  • Dynavax Technologies Corporation
  • Merck & Co., Inc.
  • Novartis AG
  • GC Biopharma
  • Bayer AG
  • Bharat Biotech
  • Sartorius AG
  • Serum Institute of India Pvt. Ltd.
  • Bio Farma

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope
    1.4    Research Methodology
2    Executive Summary
3    Global Recombinant Vaccine Market Overview

    3.1    Global Recombinant Vaccine Market Historical Value (2017-2023)
    3.2    Global Recombinant Vaccine Market Forecast Value (2024-2032)
4    Global Recombinant Vaccine Market Landscape
    4.1    Global Recombinant Vaccine Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Recombinant Vaccine Product Landscape
        4.2.1    Analysis by Type 
        4.2.2    Analysis by Disease Indication
        4.2.3    Analysis by Distribution Channel
        4.2.4    Analysis by End User
5    Global Recombinant Vaccine Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model 
    5.4    Key Demand Indicators
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
    5.7    Value Chain Analysis
6    Global Recombinant Vaccine Market Segmentation 
    6.1    Global Recombinant Vaccine Market by Type
        6.1.1    Market Overview                            
        6.1.2    Live Attenuated
        6.1.3    Subunit
    6.2    Global Recombinant Vaccine Market by Disease Indication
        6.2.1    Market Overview
        6.2.2    Hepatitis B
        6.2.3    Rotavirus 
        6.2.4    Herpes Zoster
        6.2.5    Meningococcal B
        6.2.6    Others
    6.3    Global Recombinant Vaccine Market by Distribution Channel
        6.3.1    Market Overview                                              
        6.3.2    Hospitals
        6.3.3    Vaccination Centres 
    6.4    Global Recombinant Vaccine Market by End User
        6.4.1    Market Overview
        6.4.2    Paediatrics
        6.4.3    Adults
        6.4.4    Veterinary
    6.5    Global Recombinant Vaccine Market by Region
        6.5.1    Market Overview
        6.5.2    North America 
        6.5.3    Europe
        6.5.4    Asia Pacific
        6.5.5    Latin America
        6.5.6    Middle East and Africa
7    North America Recombinant Vaccine Market
    7.1    Market Share by Country
    7.2    United States of America
    7.3    Canada
8    Europe Recombinant Vaccine Market
    8.1    Market Share by Country
    8.2    United Kingdom
    8.3    Germany
    8.4    France
    8.5    Italy
    8.6    Others
9    Asia Pacific Recombinant Vaccine Market
    9.1    Market Share by Country
    9.2    China
    9.3    Japan
    9.4    India
    9.5    ASEAN
    9.6    Australia
    9.7    Others
10    Latin America Recombinant Vaccine Market
    10.1    Market Share by Country
    10.2    Brazil
    10.3    Argentina
    10.4    Mexico
    10.5    Others
11    Middle East and Africa Recombinant Vaccine Market
    11.1    Market Share by Country
    11.2    Saudi Arabia
    11.3    United Arab Emirates
    11.4    Nigeria
    11.5    South Africa
    11.6    Others
12    Patent Analysis
    12.1    Analysis by Type of Patent
    12.2    Analysis by Publication year
    12.3    Analysis by Issuing Authority
    12.4    Analysis by Patent Age
    12.5    Analysis by CPC Analysis
    12.6    Analysis by Patent Valuation 
    12.7    Analysis by Key Players
13    Grants Analysis
    13.1    Analysis by year
    13.2    Analysis by Amount Awarded
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Grant Application
    13.5    Analysis by Funding Institute
    13.6    Analysis by NIH Departments
    13.7    Analysis by Recipient Organization
14    Funding Analysis
    14.1    Analysis by Funding Instances
    14.2    Analysis by Type of Funding
    14.3    Analysis by Funding Amount
    14.4    Analysis by Leading Players
    14.5    Analysis by Leading Investors
    14.6    Analysis by Geography
15    Partnership and Collaborations Analysis
    15.1    Analysis by Partnership Instances
    15.2    Analysis by Type of Partnership
    15.3    Analysis by Leading Players
    15.4    Analysis by Geography
16    Regulatory Framework
    16.1    Regulatory Overview
        16.1.1    US FDA
        16.1.2    EU EMA
        16.1.3    INDIA CDSCO
        16.1.4    JAPAN PMDA
        16.1.5    Others
17    Supplier Landscape
    17.1    GSK plc
        17.1.1    Financial Analysis
        17.1.2    Product Portfolio
        17.1.3    Demographic Reach and Achievements
        17.1.4    Mergers and Acquisitions
        17.1.5    Certifications
    17.2    Pfizer Inc.
        17.2.1    Financial Analysis
        17.2.2    Product Portfolio
        17.2.3    Demographic Reach and Achievements
        17.2.4    Mergers and Acquisitions
        17.2.5    Certifications
    17.3    Sanofi
        17.3.1    Financial Analysis
        17.3.2    Product Portfolio
        17.3.3    Demographic Reach and Achievements
        17.3.4    Mergers and Acquisitions
        17.3.5    Certifications
    17.4    Walvax Biotechnology Co., Ltd. (Walvax)
        17.4.1    Financial Analysis
        17.4.2    Financial Portfolio
        17.4.3    Demographic Reach and Achievements
        17.4.4    Mergers and Acquisitions
        17.4.5    Certifications
    17.5    Dynavax Technologies Corporation
        17.5.1    Financial Analysis
        17.5.2    Product Portfolio
        17.5.3    Demographic Reach and Achievements
        17.5.4    Mergers and Acquisitions
        17.5.5    Certifications
    17.6    Merck & Co., Inc.
        17.6.1    Financial Analysis
        17.6.2    Product Portfolio
        17.6.3    Demographic Reach and Achievements
        17.6.4    Mergers and Acquisitions
        17.6.5    Certifications
    17.7    Novartis AG
        17.7.1    Financial Analysis
        17.7.2    Product Portfolio
        17.7.3    Demographic Reach and Achievements
        17.7.4    Mergers and Acquisitions
        17.7.5    Certifications
    17.8    GC Biopharma
        17.8.1    Financial Analysis
        17.8.2    Product Portfolio
        17.8.3    Demographic Reach and Achievements
        17.8.4    Mergers and Acquisitions
        17.8.5    Certifications
    17.9    Bayer AG
        17.9.1    Financial Analysis
        17.9.2    Product Portfolio
        17.9.3    Demographic Reach and Achievements
        17.9.4    Mergers and Acquisitions
        17.9.5    Certifications
    17.10    Bharat Biotech
        17.10.1    Financial Analysis
        17.10.2    Product Portfolio
        17.10.3    Demographic Reach and Achievements
        17.10.4    Mergers and Acquisitions
        17.10.5    Certifications
    17.11    Sartorius AG
        17.11.1    Financial Analysis
        17.11.2    Product Portfolio
        17.11.3    Demographic Reach and Achievements
        17.11.4    Mergers and Acquisitions
        17.11.5    Certifications
    17.12    Serum Institute of India Pvt. Ltd.
        17.12.1    Financial Analysis
        17.12.2    Product Portfolio
        17.12.3    Demographic Reach and Achievements
        17.12.4    Mergers and Acquisitions
        17.12.5    Certifications
    17.13    Bio Farma
        17.13.1    Financial Analysis
        17.13.2    Product Portfolio
        17.13.3    Demographic Reach and Achievements
        17.13.4    Mergers and Acquisitions
        17.13.5    Certifications
18    Global Recombinant Vaccine Market - Distribution Model (Additional Insight)
    18.1    Overview 
    18.2    Potential Distributors 
    18.3    Key Parameters for Distribution Partner Assessment 
19    Key Opinion Leaders (KOL) Insights (Additional Insight)
20    Company Competitiveness Analysis (Additional Insight)

    20.1    Very Small Companies
    20.2    Small Companies
    20.3    Mid-Sized Companies
    20.4    Large Companies
    20.5    Very Large Companies
21    Payment Methods (Additional Insight)
    21.1    Government Funded
    21.2    Private Insurance
    21.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The global market size for recombinant vaccines reached a value of more than USD 14.91 billion in 2023.

The market is expected to grow at a CAGR of 11.9% between 2024 and 2032.

The major market drivers include increasing awareness, improved availability of recombinant vaccines, and spread of infectious diseases.

The global market size for recombinant vaccines is expected to reach a value of more than USD 41.04 billion by 2032.

The key trends of the market are advantages of recombinant vaccines, research and development by key players, and reduced expenditure and side effects of these vaccines.

Key market players include GSK plc, Pfizer Inc., Sanofi, Walvax Biotechnology Co., Ltd. (Walvax), and Dynavax Technologies Corporation, among others.

Recombinant vaccines are made with DNA recombination of yeast or bacterial cells that are embedded into the host cell to trigger an immune response.

Some examples of recombinant vaccines are vaccines against meningitis, hepatitis B, and Influenza B diseases.

The global recombinant vaccines market is segmented based on type, disease indication, end use, and region.

Recombinant vaccines are less risky, can be produced easily and are also capable of being inserted into multiple carriers.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER